2 Jul 2021

KYMOS: Adding Value to Biopharma

PNG 1.8 MB

KYMOS recently had the pleasure to lead a TV program series about the importance of outsourcing service providers like ourselves in the provision of medicines. Since the outbreak of COVID-19 the general public is paying much more attention to the biopharmaceutical industry and the challenges of conducting drug development, manufacturing, quality control and supply in the midst of a global pandemic. We invite you to watch this 2-minute English video and celebrate society's rising awareness of the key role played by the pharma and biotech sectors in our day-to-day lives.

Content provided by our supplier

Kymos Pharma Services, S.L.

  • ES
  • 2016
    On CPHI since
  • 100 - 249
Company types
Contract Service

Other Content from Kymos Pharma Services, S.L. (1)

  • News Kymos Acquires Germany’s Prolytic

    Kymos, a Contract Research Organisation (CRO) and member of CataloniaBio & HealthTech, has bought German company Prolytic GmbH in order to strengthen its activity in the biologics and advanced therapies market. The company previously acquired Italian firm Pharmaprogress in 2016.